Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.59 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.53 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.48 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.48 |
| ▸ | GPR84 | Q9NQS5 | 6/20 | 0.48 |
| ▸ | FDPS | P14324 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | LCK | P06239 | 1/20 | 0.47 |
| ▸ | PPARD | Q03181 | 1/20 | 0.47 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.47 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13267645 | 1.00 | CA1 (0.59) | CA1ACE2FFAR1FFAR4GPR84 | |
| SCHEMBL26106191 | 1.00 | CA1 (0.59) | CA1ACE2FFAR1FFAR4GPR84 | |
| SCHEMBL8898661 | 0.98 | CA1 (0.61) | CA1ACE2FFAR1FFAR4GPR84 | |
| SCHEMBL19004774 | 0.91 | CA1 (0.52) | CA1ACE2FFAR4FDPS | |
| SCHEMBL3286382 | 0.91 | CA1 (0.52) | CA1ACE2FFAR4FDPS | |
| SCHEMBL18092724 | 0.86 | BLM (0.47) | CA1ACE2FFAR1FFAR4GPR84 | |
| SCHEMBL4255452 | 0.86 | BLM (0.47) | CA1ACE2FFAR1FFAR4GPR84 | |
| SCHEMBL10904396 | 0.84 | CA1 (0.57) | CA1ACE2FFAR1FFAR4 | |
| SCHEMBL10904395 | 0.84 | CA1 (0.57) | CA1ACE2FFAR1FFAR4 | |
| SCHEMBL11115354 | 0.84 | CA1 (0.57) | CA1ACE2FFAR1FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1178031-B1 | PROCESS FOR THE PREPARATION OF ORGANIC COMPOUNDS WITH MANGANESE CATALYSTS OR THE LIKE | DAICEL CHEM (JP) | 2012-02-01 | — | — | EP | disclosed |
| US-6548713-B2 | Efficiently producing a compound having an alkyl group or alkenyl group bonded at the alpha position of an electron attractive group, by catalytic radical addition reaction with compound of Group 5,6,7,8, or 9 | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2003-04-15 | — | — | US | disclosed |
| US-20020165416-A1 | Process for the preparation of organic compounds with manganese cataylsts or the like | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2002-11-07 | — | — | US | disclosed |
| EP-1178031-A1 | PROCESS FOR THE PREPARATION OF ORGANIC COMPOUNDS WITH MANGANESE CATALYSTS OR THE LIKE | Daicel Chemical Industries, Ltd. (JP) | 2002-02-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020165416-A1 | Process for the preparation of organic compounds with manganese cataylsts or the like | SOD1, CAT, SOD3 | CA1 1250/4885ACE2 3298/4885FFAR1 1536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.